• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

The PRISM trial: Progesterone therapy does not alter birth outcomes in women with early pregnancy bleeding

byShani ChibberandDayton McMillan
May 9, 2019
in Emergency, Obstetrics, Pediatrics, Public Health
Reading Time: 2 mins read
5
Share on FacebookShare on Twitter

1. Women with early pregnancy bleeding administered progesterone experienced similar rates of live births occurring after 34 weeks’ gestation as women treated with placebo.

2. Subgroup analysis was generally inconclusive, though many subgroups had risk ratios approaching significance supporting progesterone use.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Miscarriages are not uncommon in pregnancy and are associated with various adverse outcomes. Progesterone use during pregnancy has been evaluated in various contexts as a possible treatment to support pregnancy viability. The Progesterone in Spontaneous Miscarriage (PRISM) trial evaluated if progesterone treatment for women with early pregnancy bleeding results in a higher incidence of live births than placebo treatment. Women treated with progesterone experienced similar rates of live birth as those treated with placebo. Incidence of adverse events was similar between treatment groups as well.

This large, double-blind study provides further clarity on evidence-based uses for progesterone treatment in pregnancy. Its strengths include its large sample size, randomized design, and extensive subgroup analysis. The study was limited by evaluating a single route and routine of progesterone administration and progesterone was not utilized beyond 16 weeks of gestation.

Click to read the study, published today in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

Hormonal fluctuations in the menstrual cycle may affect sleep and memory performance

Vaginal and intramuscular progesterone reduce high-risk singleton preterm birth

#VisualAbstract: A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy

Relevant Reading: Bleeding in early pregnancy

In-Depth [randomized controlled trial]: This double-blinded, placebo-controlled, randomized controlled trial enrolled women between 2015 and 2017. Eligible participants were between 16 and 39 years old, had completed 12 weeks or less of pregnancy, presented with vaginal bleeding, and had an intrauterine gestational sac visible on ultrasound. Participants were randomized into a progesterone group (n=2025) or a placebo group (n=2013). Both groups were administered treatment vaginally or rectally twice daily from the time of study enrollment through 16 weeks of gestation. The primary outcome of live birth at 34 weeks of gestation or greater occurred in 75% and 72% of progesterone and placebo groups, respectfully (relative rate [RR], 1.03; 95% CI, 1.00 to 1.07; P=0.08). Imputation analysis to correct for missing data also showed no significant difference in treatment outcomes. The incidence of miscarriage was 20% and 22% in the progesterone and placebo groups, respectfully (RR, 0.91; 95% CI, 0.81 to 1.01). The incidence of live births in women who had three or more previous miscarriages was 72% and 57% for the progesterone and placebo groups, respectfully (RR, 1.28; 95% CI, 1.08 to 1.51). Maternal or neonatal adverse events did not significantly differ between treatment groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

 

Tags: bleeding during pregnancyfirst-trimester bleedingmiscarriageprogesteronethreatened abortion
Previous Post

Ticagrelor reversal agent provides immediate and sustained effect

Next Post

Patent foramen ovale associated with four-fold increased risk for ischemic stroke in patients with pulmonary embolism

RelatedReports

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Endocrinology

Hormonal fluctuations in the menstrual cycle may affect sleep and memory performance

November 5, 2021
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Obstetrics

Vaginal and intramuscular progesterone reduce high-risk singleton preterm birth

April 12, 2021
#VisualAbstract: A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy
StudyGraphics

#VisualAbstract: A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy

August 22, 2020
Progesterone injections for short cervix do not reduce preterm birth
Obstetrics

Vaginal progesterone shows no benefit for preventing unexplained recurrent miscarriages: The PROMISE study

November 25, 2015
Next Post
High rates of over-diagnosis of pulmonary embolism by CT angiography

Patent foramen ovale associated with four-fold increased risk for ischemic stroke in patients with pulmonary embolism

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Mavacamten shows promise for treating patients with obstructive hypertrophic cardiomyopathy

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Cardiovascular outcomes of dialysis patients using phosphate binders with or without calcium

Please login to join discussion

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.